Holen Sie sich die Stockscreener-App
2.00
0.50%
-0.010
Handel nachbörslich:
2.00
Inhibikase Therapeutics Inc Aktie (IKT) Neueste Nachrichten
Dopamine Agonists Market is expected to reach US$ 1,732.41 - openPR.com
Inhibikase Therapeutics (NYSE:IKT) & Alpha Cognition (OTC:ACOGF) Head-To-Head Review - Defense World
Short Interest in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Rises By 29.0% - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) vs. Liminatus Pharma (NASDAQ:LIMN) Financial Survey - Defense World
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of “Buy” by Analysts - Defense World
Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path By Investing.com - Investing.com Nigeria
Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path - Investing.com Nigeria
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) Raised to "Strong-Buy" at HC Wainwright - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Sell at Wall Street Zen - MarketBeat
Inhibikase Therapeutics (NYSE:IKT) Receives Buy Rating from HC Wainwright - MarketBeat
H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating By Investing.com - Investing.com Nigeria
H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating - Investing.com
Inhibikase Therapeutics (IKT): HC Wainwright & Co. Issues 'Buy' Rating | IKT Stock News - GuruFocus
Contrasting Inhibikase Therapeutics (NASDAQ:IKT) and Liminatus Pharma (NASDAQ:LIMN) - Defense World
Inhibikase Therapeutics (IKT) price target decreased by 20.00% to 5.71 - MSN
Inhibikase Therapeutics Announces $93.6 Million Stock Offering - MSN
Contrasting Inhibikase Therapeutics (NYSE:IKT) and Sorrento Therapeutics (NASDAQ:SRNE) - Defense World
Is Inhibikase Therapeutics Inc. stock a safe buy before earningsOptions Trading Strategies & Low Risk Trading Growth - bollywoodhelpline.com
Inhibikase Therapeutics (NASDAQ:IKT) and Liminatus Pharma (NASDAQ:LIMN) Head to Head Contrast - Defense World
Analyzing Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
Can Inhibikase Therapeutics Inc. stock double in next 5 years2025 Technical Patterns & Free Weekly Chart Analysis and Trade Guides - Улправда
Gains Report: Why Inhibikase Therapeutics Inc. stock remains a top recommendationEarnings Summary Report & Low Risk High Reward Trade Ideas - moha.gov.vn
Will Inhibikase Therapeutics Inc. stock sustain high P E ratios2025 Market Sentiment & Growth Focused Stock Reports - Улправда
Inhibikase Updates ATM Equity Program to Raise Capital - The Globe and Mail
Inhibikase Therapeutics Updates ATM Offering Program - TradingView — Track All Markets
Is Inhibikase Therapeutics Inc. stock recession proofJuly 2025 Sentiment & Safe Entry Trade Signal Reports - DonanımHaber
Why Inhibikase Therapeutics Inc. stock remains a top recommendationQuarterly Performance Summary & Momentum Based Trading Signals - DonanımHaber
Is Inhibikase Therapeutics Inc. stock attractive for income investorsJuly 2025 Trends & Verified Swing Trading Watchlists - Улправда
Dow Update: Is Inhibikase Therapeutics Inc. stock attractive for hedge fundsJuly 2025 Big Picture & Reliable Volume Spike Alerts - Улправда
What drives Inhibikase Therapeutics Inc stock priceVolume Weighted Average Price & Free Stock Index Interpretations - earlytimes.in
While institutions invested in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) benefited from last week's 11% gain, individual investors stood to gain the most - simplywall.st
Inhibikase Therapeutics Earnings Notes - Trefis
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Strong-Buy at Cantor Fitzgerald - MarketBeat
Contrasting Inhibikase Therapeutics (NASDAQ:IKT) & Liminatus Pharma (NASDAQ:LIMN) - Defense World
Inhibikase Therapeutics (IKT) Coverage Initiated by Cantor Fitzg - GuruFocus
Cantor Fitzgerald Initiates Coverage on Inhibikase Therapeutics (NYSE:IKT) - MarketBeat
Institutions own 29% of Inhibikase Therapeutics, Inc. (NASDAQ:IKT) shares but individual investors control 41% of the company - Yahoo Finance
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded at Zacks Research - MarketBeat
Is Inhibikase Therapeutics Inc. stock near bottom after decline2025 Earnings Surprises & Low Risk Entry Point Guides - Newser
Will Inhibikase Therapeutics Inc. (IQT0) stock beat value stocksPortfolio Risk Summary & Accurate Trade Setup Notifications - Newser
Inhibikase Therapeutics sells 68.97M shares and pre-funded warrants at $1.45/share - MSN
How big funds are accumulating Inhibikase Therapeutics Inc. (IQT0) stockWeekly Trade Report & Risk Controlled Swing Alerts - Newser
Will Inhibikase Therapeutics Inc. (IQT0) stock benefit from mergersPortfolio Risk Summary & Real-Time Volume Trigger Notifications - Newser
Inhibikase Therapeutics, Inc. (IKT) -5.96% in After-hours: Shares Drop Amid Ongoing Offerings - Stocks Telegraph
Why Inhibikase Therapeutics Inc. (IQT0) stock trades below fair valueDollar Strength & High Yield Equity Trading Tips - Newser
Will Inhibikase Therapeutics Inc. (IQT0) stock draw ESG focused fundsJuly 2025 Market Mood & Fast Exit Strategy with Risk Control - Newser
Will Inhibikase Therapeutics Inc. (IQT0) stock split increase liquidityWeekly Trade Report & Weekly Breakout Watchlists - Newser
FY2025 Earnings Estimate for IKT Issued By Lifesci Capital - MarketBeat
Can Inhibikase Therapeutics Inc. stock beat market expectations this quarterTrade Entry Summary & Real-Time Buy Zone Alerts - Newser
Will Inhibikase Therapeutics Inc. stock outperform tech sector in 20252025 Market Outlook & Capital Efficient Trade Techniques - Newser
Analysts Set Expectations for IKT FY2025 Earnings - Defense World
2.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):